Pulmonx (LUNG) Osake Kurssi
Pulmonx Kurssi
Liikevaihto on kasvanut 74,3 % vuodessa viimeisten 12 vuoden aikana 90,50 M USD:een. Pulmonxn nettomarginaali on nyt −59,7 %, noussut −100,5 %:sta muutama vuosi sitten. Analyytikoiden mediaanitavoitehinta on 4,59 USD, eli yli nykyhintaa 148,8 %. 12 analyytikosta 9 suosittaa ostoa — kokonaiskonsensus on Osta.
Pulmonx osakekurssi
Pulmonx liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Pulmonx -osakkeesta
The business model of Pulmonx Corp focuses on developing and commercializing minimally invasive medical devices for the treatment of severe respiratory diseases. The company specializes in creating novel solutions for conditions like emphysema and chronic bronchitis, offering patients and healthcare providers effective alternatives to traditional treatments. Pulmonx Corp's innovative technologies, such as the Zephyr Valve System, help improve lung function and quality of life for individuals suffering from severe respiratory conditions. With a strong emphasis on research, development, and collaboration, Pulmonx Corp strives to bring about advancements in respiratory care and provide targeted therapies for patients worldwide.
Pulmonx Corp is primarily active in the medical device industry.
The main competitors of Pulmonx Corp in the market are Boston Scientific Corporation and Olympus Corporation.
Pulmonx Corp is a leading medical technology company specializing in minimally invasive devices for patients suffering from severe lung diseases. Established in 1997, Pulmonx has dedicated its efforts to improving the lives of those with chronic obstructive pulmonary disease (COPD) and severe emphysema. The company's innovative products, such as the Zephyr Valve System, offer a novel approach to lung disease treatment, providing patients with a non-surgical option that reduces hyperinflation and improves lung function. Pulmonx Corp has emerged as a global leader in the field, helping patients worldwide breathe easier and enhancing their quality of life.
Pulmonx Corp has achieved significant milestones in its journey. The company developed an innovative solution known as Zephyr Valve, which has revolutionized the treatment of severe emphysema. Pulmonx Corp received FDA approval for Zephyr Valve, making it the first minimally invasive implant to offer lung volume reduction in emphysema patients. This milestone marked a major breakthrough in the field of respiratory care. Additionally, Pulmonx Corp has expanded its global reach and established partnerships with renowned medical centers worldwide. These achievements highlight the company's commitment to improving the lives of patients suffering from debilitating lung diseases.
Pulmonx Corp is primarily present in various countries and regions around the world. These include the United States, Europe, Asia-Pacific, and Latin America.
Pulmonx Corp represents a strong commitment to improving the lives of patients with severe lung diseases. Their corporate philosophy revolves around innovation, patient-centricity, and clinical excellence. The company values inclusivity, collaboration, and integrity in their pursuit of developing novel therapeutic solutions. Pulmonx Corp focuses on providing minimally invasive devices and technologies that offer better treatment options for conditions like chronic obstructive pulmonary disease (COPD) and emphysema. With a mission to enhance lung health, Pulmonx Corp continuously strives to advance medical knowledge, improve patient outcomes, and contribute to global respiratory innovation.
Analyytikot asettavat tällä hetkellä Pulmonx-osakkeelle keskimääräisen tavoitehinnan 5,87 USD (mediaani: 4,59 USD), mikä merkitsee +217,9 % viimeisimpään hintaan verrattuna. Konsensus perustuu 12 analyytikkoarvioon.
11 analyytikkoa arvioi tällä hetkellä Pulmonx-osaketta: 8 suosittaa ostoa, 3 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Pulmonx-yhtiöltä 90,54 M USD liikevaihtoa ja −1,00 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Pulmonx-osake noteerataan hintaan 1,65 EUR (1,85 USD).
Pulmonx-osake (LUNG) on listattuna 4 pörssissä, muun muassa: NASDAQ (LUNG), Frankfurt (4NI.F), München (4NI.MU), Düsseldorf (4NI.DU).
The company Pulmonx Corp is a leading manufacturer of medical devices that help patients with respiratory diseases. The company is headquartered in Redwood City, California and has branches all over the world. Pulmonx Corp's business model is based on the development, manufacturing, and marketing of products for the treatment of lung and respiratory diseases. There are several business areas that the company serves: 1. Endobronchial therapy Pulmonx Corp has developed a unique procedure for endobronchial therapy, in which a small implant is inserted into the trachea to open the airways. The procedure is particularly effective in patients with severe emphysema or chronic obstructive pulmonary disease (COPD). 2. Diagnostics The company also offers a wide range of diagnostic tests for respiratory diseases. These tests help doctors make the correct diagnosis and plan the best treatment for the patient. 3. Training and education Pulmonx Corp also operates an extensive training and education program for doctors and medical staff. The company offers a variety of workshops and training sessions for endobronchial therapy to ensure that doctors can use the technology safely and effectively. 4. Research and development An important part of Pulmonx's business model is the continuous research and development of new products and technologies for the treatment of respiratory diseases. The company invests significant resources in developing new implants for endobronchial therapy and researching new diagnostic tests. One example of a product offered by Pulmonx Corp is the Zephyr Valve. This is a small, implantable device that is placed in the patient's bronchi. The valve allows the patient to breathe more effectively by improving lung ventilation and expanding the airways. The valve is implanted using an endobronchial catheter and can usually be done on an outpatient basis. Most patients can go home the next day. Overall, Pulmonx Corp's business model has proven to be extremely successful. The company has carved out a unique niche in the respiratory technology market and is on its way to becoming a leading provider of endobronchial therapies and diagnostic tests. The company relies on scientifically based innovations to improve the health of people with respiratory diseases.
odotettu liikevaihto Pulmonx on 90,54 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Pulmonx on −41,51 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Pulmonx:n hinta-voitto-suhde (P/E) on tällä hetkellä −1,84. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Pulmonx-osakkeen arvostusta.
Pulmonx:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,84. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Pulmonx-osakkeen arvostuskennuslukuna.
Pulmonx:n Eulpool-laatuscore on 4/10.
Pulmonx:n ISIN on US7458481014. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Pulmonx:n WKN on A2P1AF. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Pulmonx:n ticker on LUNG. Tämä pörssinoteeraus käytetään Pulmonx-osakkeiden kauppaan pörssissä.
Pulmonx osake
Pulmonx vertaisryhmä
Pulmonx Ticker
Pulmonx FIGI
Kaikki tunnusluvut ja syvällinen analyysi Pulmonx:sta
Meidän osakeanalyysimme Pulmonx-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Pulmonx:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: